Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 958-964

  Wasfy, Momtaz O ^a   Pimentel, Guillermo ^a   Abdel Maksoud, Mohammed ^a   Russell, Kevin L ^b   Barrozo, Christopher P ^b   Klena, John D ^a   Earhart, Kenneth ^a   Hajjeh, Rana ^a,c  

^a US Naval Medical Research Unit No 3 Egypt   (Egypt)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Pneumococci; Serotypes; Surveillance; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN G; STREPTOCOCCUS VACCINE; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; DIFFUSION; DRUG EFFICACY; EGYPT; HUMAN; INFECTION CONTROL; LATEX AGGLUTINATION TEST; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT EDUCATION; PENICILLIN RESISTANCE; SEROTYPING; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 21244497342     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki101     Document Type: Article

References (44)

1. Obaro SK, Monteil MA, Henderson DC. The pneumococcal problem. BMJ 1996; 312: 1521-5.
2. Rennels MB, Edwards KM, Keyerling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604-11.
3. Gertz RE, McEllistrem MC, Boxrud DJ et al. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 2003; 4: 4194-216.
4. Catterall JR. Lung infections: Streptococcus pneumoniae. Thorax 1999; 54: 929-37.
5. Arai S, Konda T, Wad A et al. Use of antiserum-coated latex particles for serotyping Streptococcus pneumoniae. Microbiol Immunol 2001; 45: 159-62.
6. Choo S, Finn A. New pneumococcal vaccines for children. Arch Dis Child 2001; 84: 289-94.
7. Robbins JB, Austrian R, Lee CJ et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1136-59.
8. Sleeman K, Knox K, George R et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis 2001; 183: 239-46.
9. Eby R. Pneumococcal conjugate vaccines. In: Powell MF, Newman MJ, eds. Pharmaceutical Biotechnology, Vol. 6. Vaccine design: the subunit and adjuvant approach. New York: Plenum, 1995; 695-718.
10. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187-95.
11. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
12. Hausdorff WP, Bryant J, Peter R et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30: 100-21.
13. Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285: 1729-35.
14. Miller E, Waight P, Efstratiou A et al. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-98. Acta Paediatr 2000; 89: 11-16.
15. Qrtqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J 2001; 18: 184-95.
16. Hausdorff WP, Bryant J, Kloek C et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000; 30: 122-40.
17. Whitney CG, Farley MM, Hadler J et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343: 1917-24.
18. Jacobs MR, Koornhof HJ, Robinson-Browen RM et al. Emergence of multiple resistance pneumococci. N Engl J Med 1978; 299: 735-40.
19. Hofmann J, Cetron MS, Farley MM et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-6.
20. Crew-Brown HH, Karstaedt AS, Saunders G et al. Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997; 25: 1165-72.
21. Benbachier M, Benredjeb S, Boye CS et al. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities. Antimicrob Agents Chemother 2001; 45: 627-9.
22. Guirguis N, Hafez K, El Kholy MA et al. Bacterial meningitis in Egypt: analysis of CSF isolates from hospital patients in Cairo, 1977-78. Bull World Health Organ 1983; 61: 517-24.
23. Ajello GW, Feeley JC, Hayes PS et al. Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. J Clin Microbiol 1984; 20: 55-8.
24. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
25. Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37: 1155-64.
26. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disc Susceptibility Tests-Eighth Edition: Approved Standard M2-A8. NCCLS, Wayne, PA, 2003
27. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, 2003
28. Jacobs MR, Bajaksouzian S, Appelbaum PC et al. Evaluation of the Etest for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis 1992; 15: 473-8.
29. Jacobs MR, Koornhof HJ, Robins-Browne RM et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 229: 735-40.
30. Goetghebuer T, West TE, Wermenbol V et al. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop Med Int Health 2000; 5: 207-13.
31. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12: 389-94.
32. Guirguis NI, Helmy MF, Mohamed MR et al. A suggested vaccine formulation for the control of pneumococcal meningitis in Egypt. J Egypt Public Health Assoc 1990; 65: 291-303.
33. Fenoll A, Jado I, Vicioso D et al. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998; 36: 3447-54.
34. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implication for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35: 547-55.
35. Scott JA, Hall AJ, Dagan R et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex and geography in 7000 episodes of invasive disease. Clin Infect Dis 1996; 22: 973-81.
36. Dagan R, Engelhard D, Piccard E. Epidemiology of invasive childhood pneumococcal infections in Israel. JAMA 1992; 268: 3328-32.
37. Rahav G, Toledano Y, Engelhard D et al. Invasive pneumococcal infections: a comparison between adults and children. Medicine 1997; 76: 295-303.
38. Shibl AM, Hussein SS. Surveillance of Streptococcus pneumoniae serotypes in Riyadh and their susceptibility to penicillin and other commonly prescribed antibiotics. JAC 1992; 29: 149-57.
39. Väkeväinen M, Eklund C, Eskola J et al. Cross-reactivity of antibodies to type 6B and 6A polysaccharides of Streptococcus pneumoniae, evoked by pneumococcal conjugate vaccines, in infants. J Infect Dis 2001; 184: 789-93.
40. Ostroff SM, Harrison LH, Khallaf N et al. Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from children with pneumoniae. Clin Infect Dis 1996; 23: 1069-74.
41. El Kholy MA, Baseem H, Hall GS et al. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. JAC 2003; 51: 625-30.
42. Doern GV, Heilmann KP, Huynh HK et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45: 1721-9.
43. Gwanzura L, Christopher P, Nathoo KJ et al. Rapid emergence of resistance to penicillin and trimethoprim-sulfamethoxazole in invasive Streptococcus pneumoniae in Zimbabwe. Int J Antimicrob Agents 2003; 21: 557-61.
44. Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to betalactam antibiotics. J Pediatr Infect Dis 1991; 10: 871-3.